Helf Maximilian J, Buntin Kathrin, Klančar Andrej, Rust Michael, Petersen Frank, Pistorius Dominik, Weber Eric, Wong Joanne, Krastel Philipp
Biomedical Research, Novartis Pharma AG, 4002 Basel, Switzerland.
Novartis d.o.o., Kolodvorska 27, 1234 Mengeš, Slovenija.
Nat Prod Rep. 2024 Dec 11;41(12):1824-1834. doi: 10.1039/d4np00022f.
Covering 1986 to presentNatural product drug discovery at Novartis has a long and successful history of delivering life saving medicines to millions of patients. In this viewpoint, we are presenting the tools we use and challenges we face as we advance natural products from early research into development and beyond. We are leveraging our collection of 90 000 microbial strains and 20 000 isolated natural products to find new medications in an interdisciplinary approach that requires expertise in microbiology, computational biology, synthetic biology, chemistry, and process development. Technological advances, particularly in genome engineering and data science have transformed our field, accelerating discovery and facilitating sustainable compound supply. Emerging new modalities such as antibody drug conjugates, radioligand therapies and xRNA-based medications offer new opportunities for natural product-derived drugs. By taking advantage of these new modalities and the most recent research technologies, natural products will significantly contribute to the medicines of the future.
涵盖1986年至今
诺华公司的天然产物药物研发有着悠久且成功的历史，为数百万患者提供了挽救生命的药物。在这一观点阐述中，我们将介绍在把天然产物从早期研究推进到开发及后续阶段过程中所使用的工具以及面临的挑战。我们正在利用我们收集的9万种微生物菌株和2万种分离出的天然产物，通过跨学科方法寻找新药物，这需要微生物学、计算生物学、合成生物学、化学和工艺开发等方面的专业知识。技术进步，特别是在基因组工程和数据科学方面的进步，已经改变了我们这个领域，加速了发现过程并促进了可持续的化合物供应。抗体药物偶联物、放射性配体疗法和基于xRNA的药物等新兴的新疗法为天然产物衍生药物提供了新机会。通过利用这些新疗法和最新的研究技术，天然产物将为未来的药物做出重大贡献。
